
Regeneron Pharmaceuticals spent this past year stacking fresh deals and clinical milestones, from the Telix radiopharmaceutical tie‑up to FDA approval of Livsayis for generalized myasthenia gravis. Investors who held Regeneron Pharmaceuticals over the past year are up 25.9%, including dividends. If you were deciding whether to buy on 19 November 2025, you would have seen that bullish and bearish analysts were 31% apart on fair value. Which story about Regeneron’s future did that spread really require you to accept?
This theme extends beyond Regeneron Pharmaceuticals. See which of 36 healthcare AI stocks may still merit a closer look.
The shares cost US$703 at the start of the period, so anyone looking at Regeneron Pharmaceuticals then had to decide which of two very different stories to lean toward.
On the upbeat side, the bullish camp saw a Fair Value of US$921, a price implied by assumptions that Dupixent and EYLEA HD could capture far greater US and global market share. That view rested on expectations of 7.9% annual revenue growth and rising profit margins, helped by manufacturing expansion and a broader oncology and hematology portfolio.
The bearish narrative pointed to a Fair Value of US$540, a level based on the idea that biosimilars and US healthcare reforms would steadily erode pricing power. That scenario assumed revenue growth of only 1.4% a year and profit margins falling to 22.5%, with EYLEA and Dupixent exposure, rising R&D costs, and demographic shifts all pressuring future earnings.
Regeneron Pharmaceuticals secured FDA approval for Livsayis in generalized myasthenia gravis and reported Q3 2026 revenue of US$5,115.8m and net income of US$1,948.7m, both above Q3 2025 levels, which leaned toward the bullish growth story. Net margin slipped from 38.9% to 38.1%, and the failed melanoma trial with resulting class actions pushed back against the idea of steadily rising profitability. Overall, the evidence cut both ways.
The key assumption investors were really testing was whether product and partnership wins outpace pricing and pipeline setbacks. For another healthcare stock, you would track whether new approvals, trial readouts, and deal flow show up in higher sales and stable or improving net margin, rather than just in headlines.
Regeneron Pharmaceuticals now trades at US$923 after a 25.9% gain over the past year. The bearish analyst Narrative on Simply Wall St places its Fair Value below that level, even while accepting strong recent execution across Dupixent, EYLEA HD and newer programs.
That Narrative hinges on whether fresh franchises and pipeline assets genuinely offset pricing, trial and legal pressures. A buyer at today’s price effectively assumes the current breadth of commercial performance and late stage drugs holds up. The question is how those risks affect that belief in durability.
"The main factor that has to go right is that Regeneron Pharmaceuticals converts its broad pipeline and newer franchises such as EYLEA HD, Libtayo, cemdisiran and Pasatru into durable earnings streams that offset pricing pressure and legal and regulatory risks."
One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all
Regeneron keeps the focus on drug pipelines and trial readouts. Your next question is where similar pressures are playing out differently.
One large peer is also leaning harder into oncology, immunology and neuroscience. Management there is trying to tilt toward higher margin specialty treatments.
That same group is reshaping its medical device arm and carving out slower pieces. It is spending heavily on early stage deals that currently weigh on reported earnings.
The bet is that these therapies and platforms eventually justify that upfront hit. If the mix shift works, this could be a very different healthcare story to examine.
One Narrative has already put a figure on it. → Uncover the company trading 17% below one Narrative's Fair Value
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com